Ubs Group Ag Vericel Corp Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Vericel Corp stock. As of the latest transaction made, Ubs Group Ag holds 117,719 shares of VCEL stock, worth $5.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

117,719

Previous 68,563 71.69%

Holding current value

$5.58 Million

Previous $2.9 Million 123.17%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$40.05 - $59.11 $1.97 Million - $2.91 Million	49,156 Added 71.69%	117,719 $6.46 Million
Q3 2024 Nov 14, 2024	BUY	$42.25 - $53.56 $263,471 - $334,000	6,236 Added 10.01%	68,563 $2.9 Million
Q2 2024 Aug 13, 2024	SELL	$41.71 - $52.9 $2.61 Million - $3.32 Million	-62,690 Reduced 50.15%	62,327 $2.86 Million
Q1 2024 May 13, 2024	BUY	$32.52 - $52.33 $963,730 - $1.55 Million	29,635 Added 31.07%	125,017 $6.5 Million
Q4 2023 Feb 09, 2024	BUY	$30.85 - $37.09 $1.71 Million - $2.06 Million	55,487 Added 139.08%	95,382 $3.4 Million
Q3 2023 Nov 09, 2023	BUY	$31.69 - $39.25 $39,137 - $48,473	1,235 Added 3.19%	39,895 $1.34 Million
Q2 2023 Aug 11, 2023	BUY	$29.0 - $38.37 $257,781 - $341,070	8,889 Added 29.86%	38,660 $1.45 Million
Q1 2023 May 12, 2023	SELL	$23.85 - $31.34 $1.29 Million - $1.69 Million	-53,896 Reduced 64.42%	29,771 $872,000
Q4 2022 Feb 08, 2023	BUY	$17.65 - $27.37 $1.43 Million - $2.21 Million	80,858 Added 2878.53%	83,667 $2.2 Million
Q3 2022 Nov 10, 2022	SELL	$22.62 - $32.54 $13,345 - $19,198	-590 Reduced 17.36%	2,809 $65,000
Q2 2022 Aug 10, 2022	SELL	$22.88 - $39.45 $797,230 - $1.37 Million	-34,844 Reduced 91.11%	3,399 $86,000
Q1 2022 May 16, 2022	SELL	$31.69 - $43.29 $2.45 Million - $3.34 Million	-77,261 Reduced 66.89%	38,243 $1.46 Million
Q4 2021 Feb 14, 2022	BUY	$35.2 - $52.6 $1.93 Million - $2.88 Million	54,700 Added 89.96%	115,504 $4.54 Million
Q3 2021 Nov 15, 2021	BUY	$46.35 - $59.75 $977,011 - $1.26 Million	21,079 Added 53.06%	60,804 $2.97 Million
Q2 2021 Aug 13, 2021	BUY	$47.2 - $67.81 $1.4 Million - $2.02 Million	29,716 Added 296.89%	39,725 $2.09 Million
Q1 2021 May 12, 2021	SELL	$30.93 - $59.48 $28.1 Million - $54 Million	-908,204 Reduced 98.91%	10,009 $556,000
Q4 2020 Feb 11, 2021	BUY	$18.53 - $31.5 $16.8 Million - $28.6 Million	907,551 Added 8512.01%	918,213 $28.4 Million
Q3 2020 Nov 12, 2020	BUY	$14.68 - $19.12 $40,869 - $53,230	2,784 Added 35.34%	10,662 $198,000
Q2 2020 Jul 31, 2020	SELL	$8.5 - $15.82 $12.5 Million - $23.2 Million	-1,467,050 Reduced 99.47%	7,878 $109,000
Q1 2020 May 01, 2020	BUY	$7.25 - $19.22 $10.3 Million - $27.4 Million	1,424,454 Added 2822.15%	1,474,928 $13.5 Million
Q4 2019 Feb 14, 2020	SELL	$13.77 - $19.2 $1.16 Million - $1.62 Million	-84,584 Reduced 62.63%	50,474 $879,000
Q3 2019 Nov 14, 2019	BUY	$14.93 - $19.83 $1.14 Million - $1.51 Million	76,301 Added 129.86%	135,058 $2.05 Million
Q2 2019 Aug 14, 2019	BUY	$15.01 - $18.89 $689,034 - $867,145	45,905 Added 357.18%	58,757 $1.11 Million
Q1 2019 May 14, 2019	BUY	$16.23 - $20.29 $189,696 - $237,149	11,688 Added 1004.12%	12,852 $225,000
Q4 2018 Feb 14, 2019	SELL	$10.77 - $18.44 $505,543 - $865,573	-46,940 Reduced 97.58%	1,164 $20,000
Q3 2018 Nov 14, 2018	BUY	$9.1 - $14.8 $437,682 - $711,835	48,097 Added 687100.0%	48,104 $681,000
Q2 2018 Aug 14, 2018	SELL	$9.6 - $14.6 $7,910 - $12,030	-824 Reduced 99.16%	7 $0
Q1 2018 May 15, 2018	BUY	$5.7 - $12.3 $4,696 - $10,135	824 Added 11771.43%	831 $9,000
Q2 2017 Aug 14, 2017	SELL	N/A	-801 Reduced 99.13%	7 $0
Q1 2017 Nov 14, 2017	BUY	N/A	808	808 $2,000

Others Institutions Holding VCEL

# of Institutions

293

Shares Held

50.7M

Call Options Held

98.2K

Put Options Held

135K

View Full List

About Vericel Corp

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.24B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

More about VCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account